10/29/2026
There’s a new development in peptide access. A temporary HHS policy opens a conditional pathway for prescription compounding of BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax through qualifying pharmacies and licensed providers.
BPC-157 is one I’m especially interested in following, particularly the research into bone and tissue repair and gut health. The findings are still early and largely based on animal studies, so more human research is definitely needed.
As a provider trained in peptide therapy, I offer consultations at TruWell Integrative Medicine to review the evidence, discuss potential risks, and explore options based on your health history and goals.
Call our office if you’re interested in peptide therapy and would like learn more.
Specific safeguards apply, and these peptides remain unapproved by the FDA. The policy does not establish their safety or effectiveness.